As part of our InPharma on-the-job series, we have organised short interviews with our ESRs to better understand first-hand what a working within an industry-focused doctoral training program looks like. Shirin Nika Dietrich, our early stage researcher (ESR) 9 started in InPharma in July 2021 at the National and Kapodistrian University of Athens, Department of Pharmacy, Section of Pharmaceutical Technology (NKUA) in Greece. At the start of 2023 she transferred to Janssen Pharmaceutica NV in Belgium for her industrial secondment. Her individual research project in InPharma focuses on the development of an in vitro method for evaluating the impact of gastrointestinal (GI) transfer on performance of enabling formulations under fed state conditions.
Can you provide an overview of your current research project?
My current research project focuses on the development of an in vitro method for evaluating the impact of gastrointestinal transfer on drug formulations in a fed state. Therefore, the first scientific objective is to understand the conditions under which drugs are transferred from the stomach through the upper small intestine after a high-calorie, high-fat meal The second scientific objective is to explore drug related physiological processes limiting oral drug absorption when amorphous solid dispersions are administered after a high-calorie, high-fat meal. The third (industrial) objective is to design, implement and preliminary evaluate the utility of the in vitro methodology in reproducing intraluminal drug data after the administration of immediate-release/enabling drug products during the fed state.
What does a typical day in your research project look like?
In my research project, each day is unique. Scientific research requires being flexible and adaptable to adjust plans as needed. With the assistance of my supervisors, I engage in activities such as planning experiments, conducting hands-on tasks, analyzing data, writing reports, problem-solving, and staying updated with literature. The dynamic nature of research means we may need to revisit plans, refine methods, and conduct additional tests.
What benefits do you see of spending half of your doctorate in the non-academic sector?
Spending half of my doctorate in the non-academic sector comes with numerous benefits. It allows me to access specialized equipment and gain in-depth knowledge of industry structures. Collaborating with industry specialists provides valuable insights and helps me build a strong professional network. Importantly, it enables the translation of research outcomes into practical applications.
How did you find your training within the industry-focused doctoral training program?
In my opinion, the industry-focused doctoral training program has been incredibly beneficial for my personal development. The program offers a wide range of engaging workshops, annual network meetings, and virtual monthly meetings. Through this program, I have learned how to effectively present my key findings through posters and presentations. Additionally, attending other presentations have provided me alternative perspectives on scientific aspects that I had not previously considered. We have also received training on scientific paper writing and gained a deeper understanding of animal studies. Overall, I have derived both scientific and non-scientific benefits from the training program.
What are your plans for the remainder of your studies within InPharma and beyond?
For the remainder of my studies within InPharma, I aim to summarize my work and set a solid foundation for the next student who continues the project. Simultaneously, I plan to start applying for jobs in the research and development field of the pharmaceutical industry. I am enthusiastic about the opportunities that lie ahead, such as contributing to new Horizon 2020 projects as a supervisor, presenter, or in other capacities. I am excited for what the future holds and look forward to embracing new possibilities.